Gontivimab

格替韦单抗

Report date: 2023/05/25 20:00:20

Base Information

Drug NameGontivimab

Drug Alias NameAnti-RSV nanobodyVR-465ALX-0171

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionRespiratory syncytial virus F protein inhibitors

TargetsRespiratory syncytial virus F protein

Therapy Area/IndicationsRespiratory Syncytial Virus InfectionsRespiratory Tract Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumBulgaria +[21]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAblynx Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAblynx Nv

Active IndicationsN/A

Inactive IndicationsRespiratory Syncytial Virus InfectionsRespiratory Tract Infections

Other Information

ATC CodeN/A